Pardes Biosciences, Inc. Common Stock
Compare this stock
PRDS Stock Report Card
$
24%
Performance
Score:
10/100
PRDS returned -43.43% in the last 12 months. Based on SPY's performance of -8.72%, its performance is below average giving it a score of 10 of 100.
Technicals
Score:
43/100
PRDS receives a 42 of 100 based on 14 indicators. 5 are bullish, 7 are bearish.
Earnings
Score:
27/100
PRDS has missed earnings 3 times in the last 20 quarters.
Profit
Score:
10/100
Out of the last 9 quarters, PRDS has had 0 profitable quarters and has increased their profits year over year on 0 of them.
Volatility
Score:
44/100
PRDS has had a lower than average amount of volatility over the last 12 months giving it a score of 43 of 100.
Pardes Biosciences, Inc. Common Stock Summary
Nasdaq / PRDS
Healthcare
Biotechnology
Pardes Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics to improve the lives of patients suffering from life-threatening disease. Its lead candidate is the PBI-0451 that is in clinical development stage to treat and prevent severe acute respiratory syndrome coronavirus 2 infections and associated diseases. The company was incorporated in 2020 and is headquartered in Carlsbad, California.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Checkout Similar Companies
PRDS scored poorly on our reportcard. Here are some similar companies and how they performed.
